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ABSTRACT
A number of activities are ongoing to reduce AMR in Botswana by improving antimicrobial utilization
across all sectors. However, there is a need to share experiences. With the objective of sharing these,
the second one day symposium was held in the University of Botswana in October 2018 involving both
private and public hospitals. In Lenmed Bokamoso hospital, ESKAPE organisms were associated with 50-
90% of clinical infections; however, there was no correlation between healthcare associated infections
(HAIs) and admission swab positivity with ESKAPE or ESBL isolates. Hang times, the time between
a prescription and IV administration, were also discussed. At Nyangabwe Hospital, the prevalence of
HAIs was 13.54%, 48.9% were laboratory confirmed of which 8.5% were blood stream infections (BSIs).
The prevalence of different bacteria causing neonatal BSIs was also investigated. At Princess Marina
Hospital, positive cultures were seen in 22.4% of blood cultures with contaminants comprising the
majority. Several activities are ongoing in Botswana across sectors as a result of the findings and will be
periodically reported to further improve antibiotic utilization.
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1. Introduction
There is recognition in Botswana that the inappropriate pre-
scribing of antibiotics increases antimicrobial resistance rates
(AMR), increasing morbidity, mortality and costs [1–4], with
a number of ongoing activities across sectors to improve
antimicrobial utilization as part of the National Action Plan
(NAP) of Botswana [5]. These include undertaking a national
point prevalence study (PPS) in hospitals to guide future anti-
biotic prescribing, initiatives to reduce healthcare associated
infections (HAIs) as well as surgical site infections (SSIs), eval-
uating the extent of prescribing of antibiotics for upper
respiratory tract infections among private GPs, and appraising
prescribing practices among primary health care facilities in
Botswana with an emphasis on antibiotics [1,4,6–8]. These
activities are already leading to improvements in antibiotic
use and surveillance of HAIs in Botswana.
This second national antibiotic symposium in Botswana
was undertaken to build on these activities. This was achieved
through sharing new research findings across sectors regard-
ing antibiotic utilization and resistance patterns, local bacterial
prevalence rates and infection prevention and control (IPC)
practices. The outputs would be used to inform future
activities in Botswana as well as be part of the implementation
of the ongoing NAP to reduce AMR rates.
2. Objectives and rationale
The theme of the symposium was ‘Antimicrobial Utilization
Research and Activities in Botswana, the Past, Present and the
Future’ held at the University of Botswana, 24 October 2018.
The objectives were to sensitize the participants on develop-
ments in the areas of AMR and to share initiatives, experi-
ences, and the findings from current activities. The outputs
were aimed particularly at improving antibiotic utilization in
both public and private hospitals, and to subsequently use the
findings as a basis for improving future antibiotic utilization as
part of the ongoing NAP. This one day symposium was fol-
lowed by a training session for new researchers interested in
conducting PPS in Botswana, building on the initial training
sessions and ongoing lessons from the first comprehensive
PPS in Botswana [1,4,5].
The meeting was chaired by Professor Amos Massele and
opened by the Dean of the Faculty of Medicine, University of
Botswana. This was followed by an update by Dr. Celda
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Tiroyakgosi on current initiatives in the development and
implementation of the Botswana NAP to contain AMR.
3. Plenary session
Dr Brighid Malone started the session by discussing factors that
may influence the development of HAIs in Lenmed-Bokamoso
Private Hospital, with HAIs known to increase morbidity, mortality
and costs [8,9]. Risk factors for HAIs include hand and environ-
mental hygiene as well as surgical and critical care instrumenta-
tion involving invasive procedures [9,10]. In a prospective study
conducted between July 2017 – September 2018, the rate of HAIs
ranged from 0–6 per 1000 in-patient days, with ESKAPE
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumo-
niae, Acinetobacter baumannii, Pseudomonas aeruginosa, and
Enterobacter species) organisms associated with 50-90% of clinical
infections and the extended spectrum beta-lactamase (ESBL) pro-
ducing bacteria with 0-25% of clinical infections. Admission swab
positivity rates ranged from 0-7% of all admissions with ESKAPE
bacteria constituting 80−100% of these and ESBL producing bac-
teria constituting 0−50% of bacteria isolates. However, no correla-
tion was found between HAIs and admission swab positivity with
ESKAPE or ESBL isolates. Overall, HAIs are not associated with
bacterial colonization during admission in Lenmed-Bokamoso
hospital. There was, however, a correlation between HAI rates
and locally prevalent bacteria causing clinical infections in hospi-
talized patients in this hospital. In view of the findings, surveillance
is ongoing in the hospital with admission swabs now being taken
from the groins of all high risk patients. All admission swabs and all
clinical infection isolates found to be positive for ESKAPE and ESBL
bacteria are notified immediately by the microbiologist to key
medical staff, the ward manager and the infection, prevention
and control team. Appropriate contact precautions are promptly
instituted. Monthly HAI and admission statistics are also now
reported to all clinicians, ward managers, pharmacy and hospital
management to increase general awareness of the issue of resis-
tant bacteria, and this is being followed up.
HAIs and its potential risk factors were also the subject of
research undertaken by Pinkie Mpinda-Joseph and colleagues
at Nyangabgwe Hospital as a substantially higher prevalence
of HAIs is often seen in developing countries [9]. This is
a concern as HAIs are preventable through good IPC practices
[9,10]. This is particularly important in countries such as
Botswana with high rates of HIV (human immunodeficiency
virus) among in-patients [1,11]. Current HAI prevalence rates
are unknown among public hospitals in Botswana. To address
this, in November 2017, a one-day PPS was undertaken in this
public tertiary hospital in the northern part of the country
through sampling the medical records of all in-patients.
Three hundred and forty seven medical records were studied
with a HAI prevalence rate of 13.54%. 48.9% were laboratory
confirmed HAIs of which 8.5% were blood stream infections
and 19.1% were SSIs. Ventilator associated pneumonia/com-
plications were 17%, and 10.6% were decubitus ulcers [8]. Risk
factors included a high injectable antibiotic use (79.2% of the
patients were on antibiotics) with 32.5% (n = 58) receiving
more than two antibiotics during their admission. Patients on
indwelling urinary catheters were 10%, and 9% were
previously hospitalized in the past 90 days. The promotion of
IPC activities in the hospital are ongoing and include training,
encouraging compliance with hand hygiene protocols and
capacity improvements as well as improved surveillance and
monitoring of activities to reduce HAI rates [8].
Pinkie Mpinda-Joseph also discussed trends in the preva-
lence of neonatal bloodstream infections (BSIs) and AMR rates
in Nyangabgwe hospital. This is because up to 71% or more of
neonates are prone to BSIs during intensive care [12], and
indiscriminate antibiotic use coupled with poor IPC practices
increases infection rates and AMR. This study was undertaken
to assess BSI rates by conducting a retrospective review of
neonatal blood culture and sensitivity test results from
January 2014 to December 2017 which involved 366 isolates.
The prevalence of bacteria causing neonatal BSIs were:
Coagulase Negative Staphylococcus species (CoNS) – 31.97%,
Enterococcus spp. – 18.03%, Klebsiella pneumoniae – 10.93%
and Staphylococcus aureus – 8.47%. There was an increased
prevalence of CoNS, Klebsiella spp., Staphylococcus aureus and
Acinetobacter spp. from 2016 with a decrease in the prevalence
of Enterococcus spp. and Escherichia coli. Regarding AMR, the
extent of ESBL producing K. pneumoniae, Enterobacter spp. and
E. coli were 55%, 15.38%, and 11.11% respectively, with
K. pneumoniae and E. coli showing an increasing trend of
ESBL producing strains. Of the S. aureus isolates, 19.35%
were methicillin resistant while 6.06% of Enterococcus spp.
were resistant to vancomycin. Acinetobacter spp. showed
100% resistance to meropenem, cephalosporins, aminoglyco-
sides and the fluoroquinolones. Interventions are ongoing to
reduce BSI rates among neonates in this hospital including
initiatives to reduce the use of third generation cephalospor-
ins and missed antibiotic doses [8].
Godfrey Mutashambara Rwegerera subsequently discussed
BSIs at Princess Marina Hospital with early diagnosis and appro-
priate treatment seen as the best approaches to improve prog-
nosis and prevent AMR. A retrospective laboratory study of all
blood cultures from 1 January 2011 to 31 December 2015
showed out of 16,824 blood cultures, a positive blood culture
was seen in 22.4%. CoNS, which were most probably contami-
nants, comprised the majority (43.0%). Of the remaining isolates,
45.8% were Gram-positive bacteria and 54.2% Gram-negative
bacteria. The predominant bacteria species isolated included
Klebisella pneumoniae – 18.3%, Staphylococcus aureus – 13.6%,
Streptococcus spp. – 11.3%, Escherichia coli – 10.3% and
Pseudomonas aeruginosa – 5.3%. Enterococcus spp. were sensitive
to vancomycin, ampicillin and penicillin at 88.2%, 56.3% and
50.9% respectively. For common Gram negative isolates, moder-
ate to high resistance patterns were observed for most antibio-
tics. There was, however, low resistance to gentamycin,
ciprofloxacin, cefotaxime, amoxycillin with clavulanic acid, piper-
acillin-tazobactam and amikacin among Escherichia coli at 12.9%,
11.8%, 13.7%, 14.0%, 5.2% and 0% respectively. There was also
low resistance for the majority of commonly tested antibiotics
including amikacin, ciprofloxacin, piperacillin-tazobactam, gen-
tamycin and ceftazidime for Pseudomonas aeruginosa. In addi-
tion, low to moderate resistance for amikacin, ciprofloxacin,
piperacillin-tazobactam, gentamycin and cefotaxime against
Enterobacter spp. These local resistance patterns necessitate
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careful selection of antibiotics for empiric use aswell as an urgent
need to improve adherence to aseptic techniques during blood
culture collection. These activities are already occurring in this
hospital and will be reported on in the future.
Pharmacists are typically involved with improving anti-
microbial use in hospitals as part of antimicrobial steward-
ship programmes (ASPs) and Drug and Therapeutics
Committees (DTCs) [13,14], although there are concerns
with the lack of ASPs in some African countries and hospi-
tals in Botswana [1,15,16]. It is widely known that delays in
administration of the initiated antibiotic is associated with
poor prognosis [17]. Keamogetse Maika discussed the role
of pharmacists with improving antimicrobial utilization in
Bokamoso Hospital by focusing on the timeliness in admin-
istration of the first dose of intravenous (IV) antibiotics
through measuring ‘hang times’ [18]. ‘Hang time’ is defined
as the time interval from writing an antibiotic prescription
on the patient’s chart to the actual administration of the
first dose of the antibiotic [18]. A prospective study was
conducted to identify potential barriers that contribute to
any delay in achieving the desired administration of the first
dose in less than one hour following a prescription.
A specific antibiotic prescription chart was introduced into
the neonatal, pediatric, and adult intensive care units (NICU,
PICU and ICU) as well as pediatric wards with a baseline
assessment carried out over 3 weeks in June 2018. The
pharmacist made ward visits to capture the times of the
prescriptions and subsequent antibiotic administration, with
only the first dose considered. The baseline compliance to
hang time < 1 hour was 18.4% in June 2018. Various inter-
ventions were instigated in July 2018 to address this includ-
ing training of staff, regular interactions with physicians,
and revising the hang time monitoring tool. Improvement
in hang time compliance to < 1 hour occurred by
August 2018, but there was a subsequent reversal after
this. The monthly hang time compliance reports from the
various wards were subsequently repeatedly discussed with
ward unit managers to improve times. Several challenges
were encountered which led to suboptimal times. These
included patient records with missing times of the initiation
of prescriptions and the administration of the first antibiotic
dose, absence of an IV cannulation kit on admission (NICU,
Pediatric wards), and the use of non-antimicrobial prescrip-
tion charts to prescribe antibiotics. These issues are cur-
rently being addressed through renewed initiatives and we
will be reporting the results in the future.
4. Conclusion and next steps
Several next steps were agreed following this interactive
symposium including progressing with further PPS studies.
Several other activities are ongoing to improve antibiotic
utilization including initiatives to reduce HAIs, SSIs, BSIs, and
hang-times and these have been documented. The outcome
of these activities will also be reported in the future provid-
ing exemplars to other sub-Saharan African countries. There
will also be future training and initiation of ASPs in
Botswana to further reduce the overuse of antibiotics.
5. Expert opinion
There is a need to share activities across sectors within countries to
improve the future use of antibiotics as countries implement and
refine their NAPs to reduce AMR. Botswana is no exception. The
sharingof research findings anddiscussions is already resulting in a
number of planned activities to improve future antibiotic prescrib-
ing in Botswana. These include always taking admission swabs in
high risk patients and all isolates subsequently found tobepositive
for ESKAPE and ESBL bacteria should be immediately notified to all
key personnel to instigate appropriate contact precautions. There
are also ongoing activities to reduce HAIs within hospitals espe-
cially around patients with identified risk factors, and this will
continue including reducing the use of third generation cephalos-
porins and addressing missed antibiotic doses. Identification of
local resistance patterns will also grow across hospitals to improve
future empiric use of antibiotics. It is also likely that hang times will
be reduced in the future with increasing focus on these.
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